Pathologists Take Note: IBM’s Watson to Attack Cancer with Help of WellPoint and Cedars-Sinai

Goal of unique collaboration is to give physicians a more accurate way to diagnose and treat many types of cancer Two noteworthy healthcare organizations will collaborate with IBM (NYSE: IBM) to explore how IBM’s Watson can be used to help physicians deliver improved outcomes to patients. The collaboration involves one major health insurer and a prominent academic medical center in Los Angeles. WellPoint, Inc. (NYSE: WLP) will interact with oncology experts at the Cedars-Sinai Cancer Institute...

Pathology Labs Might Benefit from $1 Million Challenge to Sequence the Genome of a Single Cancer Cell

Goal is to produce accurate sequence of one human cancer cell; could lead to new cancer tests Pathologists and clinical laboratory managers will find the latest “prize” for a genetic breakthrough to have direct relevance to molecular diagnostics. One million dollars will go to the first person who sequences an entire cancer cell genome, including all of the RNA, using a specific whole human genome sequencer made by Carlsbad, California-based Life Technologies (NASDAQ: LIFE). This is the fourth...

Novartis To Pay $470 million To Buy Pathology Testing Company Genoptix

Cancer Testing and Molecular Diagnostics Are Main Drivers in This Transaction In a deal with implications for independent clinical pathology laboratories, pharmaceutical giant Novartis (NYSE: NVS) announced that it would acquire pathology testing company Genoptix, Inc. (NASDAQ: GXDX). Novartis will pay $470 million in cash to acquire all the shares of Genoptix. Although the total amount of $470 million to be paid for Genoptix is nearly one-half billion dollars, one financial analyst who...
;